Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Circulation

• Publication date

  2017-10-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.117.030012PMID 29061576PMCID PMC5846470
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study

  2019cited by this paper
• “ Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs : The CVD-REAL Study ( Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors )

  2018cited by this paper
• Heart failure 2016: still more questions than answers.

  2017cited by this paper
• Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond

  2017cited by this paper
• Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.

  2017cited by this paper
• SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System.

  2017cited by this paper
• Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials

  2017cited by this paper
• Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD.

  2017cited by this paper
• Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial

  2017cited by this paper
• Liraglutide in heart failure: caution is needed

  2017cited by this paper
• GLP-1 receptor agonists and heart failure in diabetes.

  2017cited by this paper
• Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes

  2017cited by this paper
• Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?

  2017cited by this paper
• Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study

  2017cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Dapagliflozin, a Selective SGLT2 Inhibitor, Attenuated Cardiac Fibrosis by Regulating the Macrophage Polarization via STAT3 Signaling in Infarcted Rat Hearts

  2017cited by this paper
• Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs

  2017cited by this paper
• SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System

  2017cited by this paper
• Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.

  2017cited by this paper
• Do effects of sodium–glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?

  2017cited by this paper
• Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes

  2017cited by this paper
• Dapagliflozin Compared to DPP-4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All-cause Mortality in Type 2 Diabetes Patients (CVD-REAL Nordic): a multinational observational study.

  2017cited by this paper
• Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

  2017cited by this paper
• Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target.

  2017cited by this paper
• Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.

  2017cited by this paper
• Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.

  2017cited by this paper
• Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes

  2017cited by this paper
• Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial

  2017cited by this paper
• Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.

  2017cited by this paper
• Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.

  2017cited by this paper
• Effects of glycaemic management on diabetic kidney disease

  2017cited by this paper
• Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents.

  2017cited by this paper
• The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model

  2017cited by this paper
• Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

  2016cited by this paper
• Reductions in Mean 24‐Hour Ambulatory Blood Pressure After 6‐Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension

  2016cited by this paper
• Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease

  2016cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2016cited by this paper
• Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

  2016cited by this paper
• New and old agents in the management of diabetic nephropathy

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.

  2016cited by this paper
• Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

  2016cited by this paper
• EMPA-REG - the "diuretic hypothesis".

  2016cited by this paper
• Lack of evidence for a harmful effect of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta‐analysis of randomized controlled trials

  2016cited by this paper
• Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus

  2016cited by this paper
• OS 12-03 SGLT-2-INHIBITION WITH DAPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT

  2016cited by this paper
• Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

  2016cited by this paper
• OS 05-04 EMPAGLIFLOZIN EXERTS CARDIO- AND NEPHRO-PROTECTIVE EFFECTS IN COHEN-ROSENTHAL DIABETIC HYPERTENSIVE RATS

  2016cited by this paper
• Central Sympathetic Inhibition: a Neglected Approach for Treatment of Cardiac Arrhythmias?

  2016cited by this paper
• A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.

  2016cited by this paper
• Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

  2016cited by this paper
• Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

  2016cited by this paper
• Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.

  2016cited by this paper
• Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.

  2016cited by this paper
• No Need to Sugarcoat the Message: Is Cardiovascular Risk Reduction From SGLT2 Inhibition Related to Natriuresis?

  2016cited by this paper
• Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects.

  2016cited by this paper
• Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

  2016cited by this paper
• Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.

  2016cited by this paper
• The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels

  2016cited by this paper
• CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

  2016cited by this paper
• Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.

  2016cited by this paper
• Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure.

  2015cited by this paper
• Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies

  2015cited by this paper
• Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy

  2015cited by this paper
• Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+–Glucose Cotransport

  2015cited by this paper
• A different view on sodium balance

  2015cited by this paper
• Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors

  2015cited by this paper
• Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

  2015cited by this paper
• Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study

  2015cited by this paper
• Possible adverse effects of SGLT2 inhibitors on bone.

  2015cited by this paper
• Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

  2015cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

  2015cited by this paper
• The perils of clinical trials.

  2014cited by this paper
• Developmental Origins of Health and Disease Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus

  2014cited by this paper
• Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes.

  2014cited by this paper
• Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes

  2014cited by this paper
• Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction.

  2014cited by this paper
• Uric acid and risk of heart failure: a systematic review and meta‐analysis

  2014cited by this paper
• Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

  2014cited by this paper
• Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease).

  2014cited by this paper
• DTB Select: 3 | March 2014

  2014cited by this paper
• β-hydroxybutyrate: much more than a metabolite.

  2014cited by this paper
• Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

  2014cited by this paper
• Treatment of Hypertension and Metabolic Syndrome: Lowering Blood Pressure Is Not Enough for Organ Protection, New Approach-Arterial Destiffening

  2014cited by this paper
• Inhibiting Mitochondrial Na+/Ca2+ Exchange Prevents Sudden Death in a Guinea Pig Model of Heart Failure

  2014cited by this paper
• Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.

  2014cited by this paper
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

  2013cited by this paper
• Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

  2013cited by this paper
• Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

  2013cited by this paper
• Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes

  2012cited by this paper
• Association of uric acid with mortality in patients with stable coronary artery disease.

  2012cited by this paper
• Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?

  2012cited by this paper
• SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

  2012cited by this paper
• The Cardiorenal Syndrome

  2011cited by this paper
• Elevated Cytosolic Na+ Increases Mitochondrial Formation of Reactive Oxygen Species in Failing Cardiac Myocytes

  2010cited by this paper
• Avosentan for overt diabetic nephropathy.

  2010cited by this paper

• The primary preventive effect of sodium–glucose cotransporter inhibitors on chronic kidney disease in patients with type 2 diabetes: a systematic review and meta-analysis

  2026cites this paper
• Effects of SGLT2 Inhibitors on Clinical Outcomes, Symptoms, Functional Capacity, and Cardiac Remodeling in Heart Failure: A Comprehensive Systematic Review and Multidomain Meta-Analysis of Randomized Trials

  2026cites this paper
• A network meta-analysis of safety and efficacy of sodium-glucose cotransporter 2 inhibitors in heart failure patients.

  2026cites this paper
• The Use of Sodium-Glucose Cotransporter2 (SGLT2) Inhibitors in Patients with Reduced Ejection Fraction: An Integrative Review

  2025cites this paper
• Signal mining of adverse drug events related to hypovolemia caused by SGLT2 inhibitors based on FAERS database

  2025cites this paper
• Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study

  2025cites this paper
• Short-term effects of DAPAgliflozin on Lung fUNction, sleep apneas, and circulatinG surfactant protein B in Heart Failure with reduced ejection fraction (DAPA-LUNG-HF)

  2025cites this paper
• Empagliflozin Preserves Cardiomyocyte Structural Homeostasis via the Stabilization of the Integrin α5–Desmocollin-2 Adhesion Axis in Sepsis-Induced Cardiomyopathy

  2025cites this paper
• Expression of GLUT-1 and SGLT-2 in the Chorioretina of Streptozotocin-induced Diabetic Rats After Administration of Empagliflozin

  2025cites this paper
• Effect of sodium-glucose co-transporter 2 inhibitor on contrast-induced acute kidney injury and prognosis in type 2 diabetes patients undergoing percutaneous coronary intervention

  2025cites this paper
• Cost-utility analysis of dapagliflozin for the treatment of symptomatic chronic heart failure in Spain

  2025cites this paper
• Use of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors in Pulmonary Hypertension

  2025cites this paper
• Targeting Metabolic Dysfunction and Inflammation with Sotagliflozin Reverses Diastolic Dysfunction in Experimental HFpEF

  2025cites this paper
• Genomic insights about the effect of sodium-glucose cotransporter 2 inhibitors: a systematic review

  2025cites this paper
• Contemporary Perspectives on Congestion in Heart Failure: Bridging Classic Signs with Evolving Diagnostic and Therapeutic Strategies

  2025cites this paper
• Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling

  2025cites this paper
• Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i

  2025cites this paper
• Diabetes Mellitus and Associated Vascular Disease: Pathogenesis, Complications, and Evolving Treatments

  2025cites this paper
• The Short and Sweet on Sodium–Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure

  2025cites this paper
• Efficacy of Dapagliflozin in the Treatment of Type 2 Diabetes Mellitus Complicated by Coronary Heart Disease: A Meta-Analysis.

  2025cites this paper
• Therapeutic Value of SGLT2 Inhibitors in the Management of Congestive Heart Failure.

  2025cites this paper
• The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis

  2025cites this paper
• Clinical therapeutics in feline medicine: updates for old and new drugs

  2025cites this paper
• Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure

  2025cites this paper
• Water-soluble vidarabine derivatives alleviate catecholamine-induced heart failure and arrhythmia without impairing cardiac function in mice

  2025cites this paper
• Roles of Empagliflozin in Diabetic Cardiomyopathy: A Review.

  2025cites this paper
• Cardiovascular Effects of Sucrose in Experimental Animals and Humans.

  2025cites this paper
• Sodium-glucose transporter-2 inhibitors: safety and efficacy in patients with peripheral artery disease.

  2025cites this paper
• SGLT2 Inhibitors: Increasing Benefits, Continued Concerns.

  2025cites this paper
• Proteomic Signatures and Blood Adenosine Triphosphate Levels as Markers of Empagliflozin Efficacy in Type 2 Diabetes Mellitus and Heart Failure

  2025cites this paper
• WIPI1-mediated mitophagy dysfunction in ventricular remodeling associated with long-term diabetes mellitus.

  2025cites this paper
• Cardiorenal Syndrome in Heart Failure with Preserved Ejection Fraction: Insights into Pathophysiology and Recent Advances

  2025cites this paper
• SGLT2 Inhibition in Aortic Stenosis: A Therapy for the Ventricle, the Valve, or Both?

  2025cites this paper
• Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial

  2025cites this paper
• Reply to Skalidis et al.

  2025cites this paper
• Anti-inflammatory Therapies for Ischemic Heart Disease

  2025cites this paper
• Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation.

  2025cites this paper
• O Uso de Inibidores do Cotransportador Sódio-Glicose 2 (ISGLT2) nos Pacientes com Fração de Ejeção Reduzida: Uma Revisão Integrativa

  2025cites this paper
• The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review

  2025cites this paper
• Impact of sodium-glucose cotransporter-2 inhibitor use on peak VO2 in advanced heart failure patients

  2024cites this paper
• Risk of limb amputation and bone fractures with sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression

  2024cites this paper
• Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence

  2024cites this paper
• Evaluating the potential impact of sodium–glucose cotransporter‐2 inhibitor “canagliflozin” on the hepatic damage triggered by hypertension in rats

  2024cites this paper
• Empagliflozin rescues lifespan and liver senescence in naturally aged mice

  2024cites this paper
• Cardiovascular Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Updated Meta-Analysis

  2024influential citation
• JinLiDa granules alleviates cardiac hypertrophy and inflammation in diabetic cardiomyopathy by regulating TP53.

  2024cites this paper
• Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure.

  2024cites this paper
• Proximal versus distal diuretics in congestive heart failure

  2024cites this paper
• Autosis: a new form of cell death in myocardial ischemia–reperfusion injury

  2024cites this paper
• Effect of dapagliflozin on readmission and loop diuretics use in patients with acute heart failure: a retrospective propensity score-matched cohort study

  2024cites this paper
• Glyceraldehyde derivatives inspired by empagliflozin as potential anti-heart failure agents independent of glucose-lowering effects

  2024cites this paper
• Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity.

  2024cites this paper
• Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis

  2024cites this paper
• When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?

  2024cites this paper
• Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney Disease

  2024cites this paper
• Tratamento da Insuficiência Cardíaca com Inibidores de SGLT2: Uma Revisão Sistemática com Metanálise

  2024cites this paper
• Heart Failure Treatment with SGLT2 Inhibitors: A Systematic Review with Meta-Analysis

  2024cites this paper
• New Perspectives in Management of Cardiovascular Risk Among People With Diabetes

  2024cites this paper
• Os efeitos da utilização dos inibidores do cotransportador sódio-glicose 2 (iSGLT2) em arritmias cardíacas: revisão integrativa de literatura

  2024cites this paper
• Dapagliflozin in acute heart failure management: a systematic review and meta-analysis of safety and effectiveness

  2024cites this paper
• Mechanism of the cardioprotective effect of empagliflozin on diabetic nephropathy mice based on the basis of proteomics

  2024cites this paper
• Advances in SGLT2 Inhibitors for Type 2 Diabetes Management

  2024cites this paper
• Empagliflozin in Acute Myocardial Infarction Reduces No-Reflow and Preserves Cardiac Function by Preventing Endothelial Damage

  2024cites this paper
• Impact of Sodium-glucose cotransporter-2 inhibitors on Cardiovascular Outcomes of Prostate Cancer Patients Receiving Gonadotropin-Releasing Hormone Agonists.

  2024cites this paper
• Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis

  2024cites this paper
• Amputation Risk in Type II Diabetes Mellitus Patients Treated with SGLT-2 Inhibitors: A Systematic Literature Review of Randomized Clinical Trials

  2024cites this paper
• Rehospitalisation rates of heart failure patients treated with SGLT2 inhibitors as an inpatient versus post-discharge.

  2024cites this paper
• Underlying mechanisms of ketotherapy in heart failure: current evidence for clinical implementations

  2024cites this paper
• Metabolic Syndrome Nonalcoholic Steatohepatitis Male Mouse With Adeno‐Associated Viral Renin as a Novel Model for Heart Failure With Preserved Ejection Fraction

  2024cites this paper
• Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus—A Narrative Review

  2024cites this paper
• [Clinical and economic analysis of the use of dapagliflozin in patients with chronic heart failure with reduced left ventricular ejection fraction in various subgroups of standard therapy in the Russian Federation].

  2024cites this paper
• Gliflozines et insuffisance cardiaque

  2024cites this paper
• Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review.

  2023cites this paper
• Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation

  2023cites this paper
• Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin

  2023cites this paper
• The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?

  2023cites this paper
• Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multicenter, real-world cohort study.

  2023cites this paper
• New Therapeutics for Heart Failure: Focusing on cGMP Signaling

  2023cites this paper
• Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic Cardiomyopathy and Promising Therapies

  2023cites this paper
• Efficacy and safety of dapagliflozin for treating heart failure in China: A meta-analysis.

  2023cites this paper
• Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis

  2023cites this paper
• A Comprehensive Guide to Sodium Glucose Co-Transport Inhibitors.

  2023cites this paper
• Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Markers of Vascular Damage

  2023cites this paper
• Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis

  2023cites this paper
• Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease

  2023cites this paper
• Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice

  2023cites this paper
• PERIOPERATIVE DIABETIC KETOACIDOSIS ASSOCIATED WITH SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS : A SYSTEMATIC REVIEW

  2023cites this paper
• Soft robotics-enabled large animal model of HFpEF hemodynamics for device testing

  2023cites this paper
• Efficacy of double vs. standard empagliflozin dose for METabolic syndromE tReatment (DEMETER — SIRIO 11) study. Rationale and protocol of the study

  2023cites this paper
• SGLT2 inhibitors; suggested mechanism of actions in supporting post-myocardial infarction patients.

  2023cites this paper
• Targeting mitochondrial quality control for diabetic cardiomyopathy: Therapeutic potential of hypoglycemic drugs.

  2023cites this paper
• Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease

  2023cites this paper
• Metformin versus sodium glucose co-transporters inhibitors as first-line for atherosclerotic cardiovascular disease: A meta-analysis

  2023cites this paper
• [A clinical and economic analysis of the use of dapagliflozin in patients with chronic heart failure in the entire spectrum of left ventricular ejection fraction in the Russian Federation].

  2023cites this paper
• Short-term anti-remodeling effects of gliflozins in diabetic patients with heart failure and reduced ejection fraction: an explainable artificial intelligence approach

  2023cites this paper
• Theuse of LCZ-696(Sacubitril/Valsartan) and SGLT2inhibitors: A Real World Experience in a Rural African Patient with Heart Failure with Reduced Ejection Fraction (HFrEF). A Case Series

  2023cites this paper
• Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels

  2023cites this paper
• SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: A meta-analysis of randomized controlled trials.

  2023cites this paper
• Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy—A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure

  2023cites this paper
• Obesity and diabetes: the final frontier

  2023cites this paper